ASH 2021 | Real world use of CAR T-cell therapy in multiple myeloma
Luciano Costa
• 12 Dec 2021
Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma who have undergone 4 or more prior therapies. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the number of patients who are able to receive ide-cel. Data from the Flatiron Health Electronic Health Record (EHR) suggests fewer than 15% of patients are eligible for treatment, with a number of patients dying before being eligible. Dr Costa thus highlights the need to approve CAR T-cell therapies for earlier lines of treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
